Results 161 to 170 of about 737,831 (320)
Molecular Oncology, EarlyView.Human cytomegalovirus infection is common in normal prostate epithelium, prostate tumor tissue, and prostate cancer cell lines. CMV promotes cell survival, proliferation, and androgen receptor signaling. Anti‐CMV pharmaceutical compounds in clinical use inhibited cell expansion in prostate cancer models in vitro and in vivo, motivating investigation ...
Johanna Classon +13 more
wiley +1 more source
Molecular Oncology, EarlyView.Rolig, Peng, and colleagues have shed new light on how dual blockade of PD1 and LAG3 enhances antitumor immunity. They found that response to immunotherapy with anti‐PD1 + anti‐LAG3 was associated with reprogramming of canonically suppressive CD4+ regulatory T cells to an inflammatory state.
Tullia C. Bruno, Anthony R. Cillo
wiley +1 more source
Synergistic drug combinations prediction by integrating pharmacological data
Synthetic and Systems Biotechnology, 2019 There is compelling evidence that synergistic drug combinations have become promising strategies for combating complex diseases, and they have evident predominance comparing to traditional one drug - one disease approaches.
Chengzhi Zhang, Guiying Yan
doaj
Determining Animal Drug Combinations Based on Efficacy and Safety
, 1986 D. D. Kratzer, Shu Geng
openalex +1 more source
Drug combinations and impaired renal function – the ‘triple whammy’ [PDF]
, 2004 Katarzyna K. Loboz, Gillian M. Shenfield
openalex +1 more source
Molecular Oncology, EarlyView.In luminal (ER+) breast carcinoma (BC), miRNA profiling identified miR‐195‐5p as a key regulator of proliferation that targets CHEK1, CDC25A, and CCNE1. High CHEK1 expression correlates with worse relapse‐free survival after chemotherapy, especially in patients with luminal A subtype.
Veronika Boušková +14 more
wiley +1 more source
Susceptibility of Mycobacterium malmoense to antibacterial drugs and drug combinations
, 1993 Sven Hoffner +2 more
openalex +1 more source
Chimeric diphtheria toxin–CCL8 cytotoxic peptide for breast cancer management
Molecular Oncology, EarlyView.DTCCL8 is a recombinant fusion toxin that targets cancer cells expressing chemokine receptors. By combining diphtheria toxin with CCL8, DTCCL8 binds to multiple receptors on tumor cells and induces selective cytotoxicity. This strategy enables receptor‐mediated targeting of cancer and may support the development of chemokine‐guided therapeutics ...
Bernardo Chavez +5 more
wiley +1 more source
Medisan, 2010 Se realizó una investigación enmarcada en los estudios de utilización de medicamentos del tipo indicación-prescripción, que incluyó a 50 pacientes con insuficiencia cardíaca, ingresados en el Hospital General Docente "Dr.
Ana Ibis Bosch Núñez +1 more
doaj
Assessingin vitrocombinations of antifungal drugs against yeasts and filamentous fungi: comparison of different drug interaction models [PDF]
, 2005 Joseph Meletiadis +4 more
openalex +1 more source